RFX6-mediated dysregulation defines human β cell dysfunction in early type 2 diabetes

John T. Walker(Western University), Marcela Briššová(Vanderbilt University Medical Center), Samir Agarwala(University of Michigan), Dale L. Greiner(University of Massachusetts Chan Medical School), Simin Fan(University of Michigan), Yasminye D. Pettway(Vanderbilt University), Conrad Reihsmann(Vanderbilt University Medical Center), Nathaniel Hart(Vanderbilt University Medical Center), Alexander L. Hopkirk(Vanderbilt University Medical Center), Leonard D. Shultz(Jackson Laboratory), Vivek Rai(University of Michigan), Alvin C. Powers(Diabetes Australia), Yicheng Tao(University of Michigan), Chunhua Dai(Diabetes Australia), Peter Orchard(University of Michigan), Rita Bottino(Children's Hospital of Pittsburgh), Stephen C.J. Parker(University of Michigan), Greg Poffenberger(Vanderbilt University Medical Center), Diane C. Saunders(Vanderbilt University Medical Center), Shristi Shrestha(HudsonAlpha Institute for Biotechnology), Christa Ventresca(University of Michigan), Jie Liu(University of Michigan), J. J. Wright(Cincinnati Children's Hospital Medical Center), Regina Jenkins(Vanderbilt University Medical Center), Radhika Aramandla(Vanderbilt University Medical Center), Arushi Varshney(University of Michigan)
bioRxiv (Cold Spring Harbor Laboratory)
December 17, 2021
Cited by 9


Related Papers